Diagnostyka+

Management Report

on the operations of Diagnostyka S.A.
and the Diagnostyka Group in the six months
ended 30 June 2026

9 September 2026

H1 2026 summary

91.3 million

tests sold in H1 2026

~ 1,300

own specimen collection points

157

diagnostic laboratories

28

diagnostic imaging centres

PLN 1.37 billion

revenue of the Diagnostyka Group, including PLN 1.35 billion in revenue from contracts with customers

PLN 334.0 million

Recurring EBITDA[1] (PLN)

PLN 139.9 million

Net profit attributable to owners of the Parent (PLN)

[1] The Group defines EBITDA as net profit (loss) adjusted for income tax, share of profit or loss of associates or jointly controlled entities, impairment losses on investments in associates and jointly controlled entities for the period, finance costs, finance income, depreciation and amortisation. Recurring EBITDA is defined as EBITDA additionally adjusted for IPO costs, the IPO-linked share-based payment plan and other one-off items (e.g. transaction advisory fees).

Letter from the President of the Management Board

Dear Shareholders and Investors,

I am pleased to present the Diagnostyka Group's results for the first six months of 2026. Throughout the period, we remained firmly focused on delivering our strategy, improving our offering for patients, and making investments that will support the Group's continued growth. At the same time, we pursued our mission to improve the health of people in Poland, building our expertise in digital healthcare services and preventive healthcare. We also reinforced the foundations of our business and prepared the Group for new projects designed to strengthen our market leadership and further build the trust of patients and partners.

In the first half of 2026, the Diagnostyka Group generated PLN 1.35 billion in revenue from contracts with customers, 14.8% more than a year earlier. The higher revenue figure reflected an 11.9% year-on-year growth in the average price per test, including 10.0% in the medical laboratory testing segment, and a 2.6% increase in test volumes. Through April 2025, we continued to provide laboratory testing under the Profilaktyka 40 PLUS programme, which generated significant service volumes. Since May 2025, the Group has been performing tests commissioned by B2B customers under the Moje Zdrowie (My Health) programme, and in June 2025 it joined the Cervical Cancer Prevention Programme as a provider under direct contracts with the National Health Fund (NFZ). The Group's recurring EBITDA rose by 6.3% year on year in the first six months of 2026, to PLN 334.0 million. In June 2026, Diagnostyka also paid a dividend for 2025, totalling PLN 148.5 million.

Patients remain at the heart of everything we do. In the first half of the year, we expanded our nationwide network of specimen collection points, which now comprises approximately 1,300 locations. We broadened our range of tests in areas including neurology, allergology, oncology and pharmacogenetics. The scale and breadth of our diagnostic services portfolio are reflected in the numbers: we currently offer more than 4,300 different tests.

Providing easy access to a broad range of diagnostic tests needs to go hand in hand with education and preventive healthcare – both essential elements of a modern healthcare system. This is why we consistently encourage regular testing by developing our services and pursuing social and educational initiatives that contribute to long-term improvements in the health of people in Poland.

In the six months to 30 June 2026, we continued to develop tools that make it easier for patients to use our services. New features were added to the D+ app to improve the patient experience. We also significantly expanded the functionalities of the Patient Portal, an important channel for accessing test results, particularly for patients who do not use the mobile app. Enhancements included simpler login via mObywatel (Poland's national digital identity app), easier access to historical test results, and a feature enabling sharing results with family members. Work also advanced on xLAB, our new laboratory system, which will ultimately replace eLAB. In the first half of 2026, we rolled out centralised test registration to further locations.

We made further progress in building the Group's capabilities in diagnostic imaging, integrating IT systems, developing our central call centre and implementing AI-based solutions to improve the quality and efficiency of our services. In the medical laboratory testing segment, in July we won a tender that expanded both the scope and value of our contract with Penta Hospitals, Poland's largest hospital owner in the private healthcare sector. The contract will increase the number of facilities we serve and the volume of tests we perform.

In line with our strategy of combining organic growth with targeted acquisitions, we continued to invest in the construction of modern laboratories in Gdynia and Gliwice in the first half of 2026. Once completed, these facilities will increase our operational capacity and enable us to respond even more effectively to the growing needs of patients and healthcare providers. At the same time, further acquisitions allowed us to expand our network and improve patients' access to diagnostic testing. During the first half of 2026, we completed eight acquisitions in the medical laboratory testing segment and three in the diagnostic imaging segment. We remain committed to a selective approach to M&A.

We also took steps to develop the Group's management capabilities. I am pleased to announce that Jakub Tatak joined the Management Board of Diagnostyka S.A. at the beginning of September as Vice President of the Management Board and Chief Financial Officer (CFO). His extensive experience in the healthcare sector, finance, M&A and organisational transformation will support the execution of our strategy and the Group's continued growth.

I would like to thank our Shareholders, Partners and the entire Diagnostyka team for their trust, professionalism and commitment. Their contribution enables us to pursue our ambitious goals and continue to develop the Group. I believe that the steps we are taking will support the Group's further sustainable value growth.

Yours sincerely,

Jakub Swadźba,
President of the Diagnostyka Management Board,
Chief Executive Officer

Diagnostic tests volume (million)

91.3 million in H1 2026



Revenue from contracts with customers (PLN million)

PLN 1,354 million in H1 2026



Recurring EBITDA (PLN million)

PLN 334.0 million in H1 2026



The first half of 2026 demonstrated the effectiveness of our growth strategy. Driven by strong organic expansion and selective acquisitions, the Diagnostyka Group strengthened its market position and maintained robust momentum.

In the six months ended 30 June 2026, the Group generated PLN 1.354 billion in revenue from contracts with customers, up 14.8% year on year, supported by a combination of higher prices and increased test volumes. The average test price rose by 11.9%, including 10.0% in medical laboratory testing services, and the volume of tests grew by 2.6% year on year. Through April 2025, we continued to provide laboratory testing under the Profilaktyka 40 PLUS programme, which generated significant service volumes. Since May 2025, the Group has been performing tests commissioned by B2B customers under the Moje Zdrowie (My Health) programme, and in June 2025 it joined the Cervical Cancer Prevention Programme as a provider under direct contracts with the National Health Fund (NFZ).

The Group's recurring EBITDA increased by 6.3% year on year to PLN 334.0 million in the first six months of 2026, translating into a recurring EBITDA margin of 24.7%. Net profit attributable to owners of the Parent improved by 2.4% year on year, reaching PLN 139.9 million. In June 2026, Diagnostyka distributed a dividend for 2025 totalling PLN 148.5 million, or PLN 4.40 per share. The dividend payout ratio was 59.0%.

Bartosz Cieślicki
Deputy Chief Financial Officer, Diagnostyka S.A.

Recurring EBITDA margin is calculated as the ratio of recurring EBITDA to revenue from contracts with customers.

Consolidated financial highlights of the Diagnostyka Group

	2024	2025	H1 2025	H1 2026
Revenue (PLN thousand)	1,974,088	2,424,233	1,188,224	1,367,798
of which revenue from contracts with customers (PLN thousand)	1,950,147	2,410,467	1,179,855	1,353,932
Increase/(decrease) in revenue from contracts with customers (%)	22.8%	23.6%	22.7%	14.8%
Organic growth/(decline) (%)	20.7%	17.9%	17.3%	12.3%
Increase/(decrease) in total diagnostic tests volume (%)	14.8%	8.1%	8.0%	2.6%
Increase/(decrease) in average price of tests sold (%)	7.3%	15.0%	13.9%	11.9%
Operating expenses (PLN thousand)	1,636,677	2,041,532	973,194	1,149,651
EBITDA (PLN thousand)	499,536	584,495	312,234	334,005
Recurring EBITDA (PLN thousand)	508,662	586,357	314,096	334,005
Recurring EBITDA margin (%)	26.1%	24.3%	26.6%	24.7%
Net profit (PLN thousand)	231,959	261,874	141,866	146,378
Net profit attributable to owners of the Parent (PLN thousand)	223,326	251,603	136,668	139,947
Dividend for the financial year (PLN thousand)	111,734	148,529	-	-
Dividend per share (DPS)	3.31	4.40	-	-
Dividend payout ratio[1] (%)	50.0%	59.0%	-	-
EPS[2]	6.62	7.45	4.05	4.15
FCF[3] (PLN thousand)	426,312	541,179	294,250	261,956
FCF/EBITDA (%)	85.3%	92.6%	94.2%	78.4%
Net debt (PLN thousand)	928,905	1,062,221	981,930	1,203,945
Net debt[4]/EBITDA	1.9x	1.8x	1.8x	2.0x

[1] Based on net profit attributable to owners of the Parent.

[2] EPS (earnings per share) is calculated by dividing net profit attributable to owners of the Parent by the total number of Company shares (i.e. 33,756,500 shares).

[3] FCF (free cash flow) is defined as EBITDA less (i) income tax paid; and (ii) adjustments resulting from changes in working capital disclosed in the consolidated statement of cash flows.

[4] Net debt is calculated by the Group as the sum of current and non-current borrowings and current and non-current lease liabilities less cash and cash equivalents as disclosed in the consolidated statement of financial position.

Table of contents

Diagnostyka+

Business profile

Mission and vision

Mission

We support good health and longevity through high-quality diagnostics

Vision

We aim to set global standards in diagnostic and preventive healthcare

Overview of the Group's operations

We are a major provider of diagnostic services, operating the largest network of medical diagnostic laboratories and specimen collection points in Poland.

Since its establishment in 1998, Diagnostyka has consistently built its leading position in terms of the number of laboratories and specimen collection points it operates, the volume of tests performed, the size of its specialist workforce and the scale of its proprietary courier network. We are also expanding rapidly in medical diagnostic imaging, investing in cutting-edge medical equipment and developing a network of facilities offering ultrasound scans, X-ray, computed tomography, and magnetic resonance imaging examinations. Medical diagnostic imaging is a key strategic growth area for our Group, allowing us to deliver an extensive range of diagnostic services within an integrated service portfolio.

We serve both the B2C segment (individual customers) and the B2B segment (public and private entities), offering comprehensive services, from the collection and transport of biological specimens to testing and delivering results to patients and partner medical establishments, usually in the shortest possible time, and always with a focus on the highest standards of quality and timeliness.

Diagnostyka has developed one of the most recognised healthcare brands in Poland. Our offering also reflects the growing focus on longevity (Longevity+ programme), with tests designed to support patients' long-term health and quality of life.

We maintain close proximity to patients through a nationwide network of approximately 1,300 specimen collection points across about 500 locations.

We operate 157 diagnostic laboratories and 28 diagnostic imaging centres.

We continue to grow organically and through selective acquisitions, steadily reinforcing our market position and broadening our service portfolio.

Diagnostyka Group offering:

Diagnostyka+ laboratoryjna

- basic tests
- specialist tests in the following areas:
  - microbiology
  - autoimmunity
  - toxicology
  - molecular biology

Diagnostyka+ genetyczna

- human genome testing
- consultations and counselling by clinical geneticists

Diagnostyka+ histopatologiczna

- histopathological examinations
- immunohistochemical tests
- cytology tests
- cytogenetics tests
- consultations by pathologists

Diagnostyka+ obrazowa

- X-ray examinations
- computed tomography (CT)
- ultrasound scans
- magnetic resonance imaging (MRI)
- image interpretation by radiologists

Diagnostyka+ kompleksowa

Longevity+

Key business areas

As part of our core business, we provide end-to-end medical diagnostic services in the following areas:

- Medical laboratory testing services
- Genetic diagnostics
- Histopathological diagnostics
- Medical diagnostic imaging
- Comprehensive diagnostics

Comprehensive diagnostic services: one-stop-shop

Network of laboratories and specimen collection points

We have a nationwide network of approximately 1,300 specimen collection points across about 500 locations. Based on our estimates, around 80% of Poland's population lives within 10 km of one of our collection points.

Our laboratory network follows a hub-and-spoke model. We focus on fast-growing areas like genetic testing and histo-pathological diagnostics. Alongside our core medical laboratory testing business, we are actively growing our diagnostic imaging network.

Map of laboratories and specimen collection points



An extensive hub-and-spoke network means:

Easy access	Better quality control	Advanced, specialised services
Scalability	Operational efficiency	Data integration

Key drivers of the Group's successful growth

The Diagnostyka Group is the provider of choice for medical laboratory testing services and the most recognisable laboratory diagnostics brand in Poland. Its success is driven by:

Wide range of tests offered and performed in the Group's laboratories

Short turnaround time from specimen collection to test results

Widest collection point network among Poland's medical laboratory testing service providers

Advanced IT infrastructure enabling integration with institutional customers

High quality of testing, confirmed by relevant certifications

Ability to meet diverse needs of a broad customer base

High-quality customer service at collection points, supported by easy access to the Group's offer via e-commerce platforms

Regional structure of operations

The Group's medical laboratory testing business is organised into six macro-regions:

- Central-Eastern Poland
- Central-Western Poland
- South-Central Poland
- South-Eastern Poland
- South-Western Poland
- Pomerania

This organisational model supports efficient operational management and ensures the effective delivery of diagnostic services nationwide.

Regional structure of operations in medical laboratory testing services

Customer segments

As part of its core business, the Diagnostyka Group provides medical laboratory testing and diagnostic imaging services to two customer segments: individual (B2C) and institutional (B2B) customers.

Revenue from contracts with customers in H1 2026

B2B ~63%
public and private entities, including physicians, outpatient clinics, and hospitals that commission diagnostic tests



B2C ~37%
individual customers

Revenue from sale of goods for resale accounted for 0.17% of revenue from contracts with customers.

Strategic value and benefits from operating in both channels:

- Diversified base of customers and payers
- Channel-specific growth strategies
- Transfer of best practices across segments
- Better understanding of customer needs
- Limited exposure to public outsourcing
- Majority of revenue linked to prices that can be adjusted, for example, in response to inflation
- Easier entry into new market segments

(B2C) Individual customers

Individual customers are private individuals who access our services:

+ by purchasing tests directly at specimen collection points, diagnostic imaging centres or clinics; or
+ through our e-commerce platforms integrated with the Group's website and the D+ mobile app.

In the six months ended 30 June 2026, services provided to individuals accounted for around 37% of the Group's revenue from contracts with customers. We believe our presence in this customer segment helps reduce our exposure to price competition in the institutional segment.

(B2B) Institutional customers

Our institutional customers include both public and private entities, such as:

+ healthcare providers, from small medical practices and outpatient clinics to small and medium-sized hospitals and nationwide medical networks, which commission diagnostic tests either through contracts with the National Health Fund (NFZ) or on a commercial basis;
+ other organisations (including companies operating in medicine-related sectors), such as universities, research and development centres, scientific and clinical research institutions, and dietitians.

In the first six months of 2026, institutional customers generated approximately 63% of the Group's revenue from contracts with customers.

Diagnostyka+

Growth strategy and prospects

Growth strategy and prospects

The growth of the Diagnostyka Group is driven by a combination of organic expansion (in terms of both volume and pricing), strategic acquisitions, and disciplined financial management.

The main strategic priorities include:

- increasing the Group's share of the diagnostic imaging market,
- developing and optimising the laboratory network,
- exploring new sales channels, including Longevity+ (comprehensive diagnostics).

Multi-dimensional growth strategy with limited risk

Organic growth	Fuelled by market growth and involving rising volumes and prices
Optimisation of the laboratory and specimen collection point network	Economies of scale and greater cost efficiency from the rationalisation of the specimen collection point network and centralisation of laboratories and courier networks
Reinforcement of central functions	Development of central functions, administrative support, and advanced IT and AI solutions
Continued expansion in the diagnostic imaging market	Selective M&A activity alongside organic growth
Longevity+	Expansion in the comprehensive diagnostics market segment by building on the existing customer base and infrastructure

Multi-path diversified growth framework underpinned by years of experience

Medical laboratory testing operations

Robust organic growth with a positive mix effect

Growth in volumes and prices across the B2B and B2C segments

Optimisation measures

Optimisation of the laboratory network

Centralising the laboratory network and optimising processes to increase efficiency

Optimisation of the specimen collection point network

Developing the network by enlarging existing specimen collection points and consolidating smaller sites

Optimisation of logistics

Centralising the courier network and warehouse logistics

Corporate functions



Scaling of the organisation

Expanding back-office functions to support further growth and rising test volumes

Forward-looking IT strategy with AI integration

Investing in IT to enhance laboratory operations and support the B2C segment by improving customer experience

Leveraging AI solutions to improve quality and reduce costs

Medical diagnostic imaging

Expansion in medical diagnostic imaging

Organic and inorganic growth

Longevity+ offering

Expansion in comprehensive healthcare

Offering diagnostic packages focused on preventive medicine in a fee-for-service model

Leveraging Diagnostyka's existing customer base and infrastructure to enable cross-selling

Selling services in the B2C model

Strategic competitive advantages

1. Market leader
in medical laboratory testing, leveraging economies of scale

2. Strong and growing position
in the diagnostic imaging market

3. Unique financial profile
in terms of growth, profitability, cash conversion, and return on invested capital

4. Comprehensive, easy-to-access service offering
tailored to meet the needs of both customers and partners

5. Diversified revenue streams
from a multi-channel business model with a broad mix of payers

6. Modern and well-developed infrastructure
including diagnostic facilities and in-house logistics

7. Experienced and effective management team
with proven ability to attract and retain top talent

8. Innovation leader
in diagnostics thanks to unique and highly specialised IT solutions

9. Brand strength
– market-leading recognition and awareness

10. Market consolidation leader
11 M&A transactions in H1 2026 (eight in the medical laboratory testing segment and three in the diagnostic imaging segment)
Total number of M&As from 2011 to H1 2026: 164

11. Full ESG transparency
in environmental protection, social responsibility, and corporate governance

Material agreements

Acquisitions During the six months ended 30 June 2026, the Group carried out the following business acquisitions:

Entities acquired in 2026	Allocation to CGU[1]	Principal business	Acquisition date	% of shares acquired	% of non-controlling interests
Acquired businesses:					
Laboratorium Hormonalno Analityczne Teresa Joanna Gago	Pasłęk	medical laboratory testing services	1 Feb 2026	100%	0%
Prywatne Laboratorium Analiz i Usług Medycznych	Kielce Lab Centralny	medical laboratory testing services	1 Feb 2026	100%	0%
Euroimmun Polska sp. z o.o.	Wrocław Lab Centralny	medical laboratory testing services	1 Mar 2026	100%	0%
NZOZ Laboratorium Analiz Lekarskich Grzegorz Pietrzak Września	Poznań Lab Centralny	medical laboratory testing services	1 Mar 2026	100%	0%
NZOZ Labomed Chorzów	Katowice Lab Paderewskiego	medical laboratory testing services	1 Jun 2026	100%	0%
Acquisition of control:					
Diagnostyka Skamed Rezonans Sp. z o.o.	Skamed	diagnostic imaging services	19 Jan 2026	61%	39%
LAB-AD Sp. z o.o.	Lab-AD	medical laboratory testing services	30 Jan 2026	100%	0%
Instytut Mikroekologii Sp. z o.o.	Instytut Mikrobiologii	medical laboratory testing services	26 Feb 2026	100%	0%
Podkarpackie Centrum Genetyczne Oncogenlab Sp. z o.o.	OncoGenLab	diagnostic imaging services	30 Apr 2026	100%	0%
Wałowamed Sp. z o.o.	Wałowamed	diagnostic imaging services	12 May 2026	70%	30%

[1] Allocation to cash-generating unit (CGU).
* The data in the columns are presented rounded to whole percentages.
Details of the acquisitions are provided in Note 21.1 to the consolidated financial statements for the six months ended 30 June 2026.

Acquisitions after the reporting date

- On 14 August 2026, the Parent entered into an agreement to acquire a 63.7% equity interest in Aidport Sp. z o.o. of Skórzewo for PLN 23,676 thousand.
- On 10 August 2026, Diagnostyka Wyrobek Sp. z o.o. acquired a 10% non-controlling interest in Diagnostyka Obrazowa Bielsko-Biała Sp. z o.o. of Kraków for PLN 200 thousand. Following the transaction, Diagnostyka Wyrobek Sp. z o.o. became the sole shareholder (holding 100% of shares), and the Group's equity interest in the entity increased to 78.66% (the sum of shares controlled directly and indirectly).
- On 30 July 2026, the Company acquired the residual 10.05% non-controlling interest in Livmed Sp. z o.o. of Nowy Tomyśl for PLN 4,646 thousand. As a result, the Company’s equity interest in the entity rose to 100%.

For details of acquisitions completed after the reporting date, see Note 25 to the consolidated financial statements for the six months ended 30 June 2026.

Agreements with leading healthcare providers

- The Diagnostyka Group provides diagnostic services, including laboratory, imaging, and serological diagnostics, based on contracts with private and public entities, ensuring priority access in emergencies and compliance with applicable legal and quality standards. It also provides outsourced services to hospitals, including diagnostic testing and blood bank operations, in line with regulatory requirements.
- Contracts with the National Health Fund (NFZ): NFZ is one of the Group’s key trading partners. As part of its strategy, the Group acquires majority stakes in regional diagnostic imaging providers that hold NFZ contracts. Contracts are executed with the relevant branches of the NFZ.
- Other laboratory diagnostics outsourcing contracts: Key agreements entered into by the Group in the ordinary course of business also include laboratory diagnostics outsourcing contracts with public and private hospitals.

Material agreements executed outside of the ordinary course of the Group’s business

- Credit facility and other financing agreements.

Information on the Group’s borrowings is provided in Note 19 to the consolidated financial statements for the six months ended 30 June 2026.

For details of events subsequent to the reporting date, see Note 25 to the consolidated financial statements for the six months ended 30 June 2026.

Key drivers of the Group's performance over the next quarters

1. Market, macroeconomic and socio-economic trends driving volumes and pricing in the medical laboratory testing and diagnostic imaging market

- Growth potential of the diagnostics market in Poland, setting it apart from other European markets.
- Increasing life expectancy, contributing to a high incidence of age-related illnesses such as diabetes, cardiovascular diseases, and cancer.
- A rise in chronic diseases, leading to greater demand for comprehensive diagnostic services.
- Ageing population.
- Advancements in telemedicine and remote diagnostics.
- Growing public awareness of healthy-lifestyle choices.
- Rising incomes and affluence levels.
- Upside potential in the pricing of medical laboratory testing and diagnostic imaging services, which remains lower in Poland than in Western European countries.
- Characteristics of the Polish market, with its fee-for-service model, low test prices relative to Western Europe, and a rising share of private spending in the diagnostics sector.
- Government-led initiatives, including preventive healthcare programmes, contributing to growing demand for diagnostic services.
- Changes in the B2C and B2B segments: in B2C, a growing number of patients are willing to pay out of pocket for tests; in the B2B channel, numerous public healthcare institutions, particularly hospitals, are outsourcing diagnostic services to private laboratories.
- Changes to NFZ funding for diagnostic imaging services.

2. Organic growth and M&A

- The Group's strategy combines volume- and price-driven organic expansion with selective acquisitions and disciplined financial management.
- Our strong asset base, comprising a nationwide network of laboratories and specimen collection points, provides a solid platform for continued organic growth.
- Consistent execution of an M&A strategy, consolidating the Group's position in Poland's fragmented medical laboratory market through selective acquisitions.
- A core priority is to grow our share in the diagnostic imaging market.
- Opening new sales channels by leveraging the Group's existing customer base and infrastructure, including the Longevity+ platform.

3. Progressing automation and digitalisation in healthcare services and the advancement of AI The Group ranks among the most innovative organisations in the medical sector, continuously building its expertise in:

- Laboratory automation.
- Robotisation of processes.
- Digital transformation.
- Exploration of the potential of artificial intelligence (AI) across various application areas, including:
  + Diagnostyka's mobile application – featuring the AI virtual assistant LiDia, the Profilaktometr module, and support for the interpretation of selected test results
  + radiology – accelerating scanning workflows and assisting with the preparation of image interpretation reports for radiology examinations

4. Wage pressure, competition for skilled healthcare personnel, and rising employee benefit costs

- We are facing challenges such as increasing wage pressure, growing competition for medical professionals, and an ageing workforce, all of which may impact our future financial performance.
- Strategic management of employee compensation and retention will be key to maintaining our competitive edge.
- Employee benefits expense, representing the largest component of the Group's operating expenses, has risen significantly in recent years, mainly due to headcount growth, higher wages, and regulatory changes, including the Healthcare Sector Minimum Wages Act.

5. Increase in operating expenses other than personnel costs

- The costs of consumables, energy, services (compensation paid to physicians employed under B2B contracts) are a significant component of the Group's operating expenses.
- The cost of consumables and energy depends on test volumes, the type of materials used, and energy prices.

Risks

Operational risks

- Cyber-attacks, security breaches, service disruptions, vendor errors or serious issues with the Group's IT infrastructure may have a material adverse effect on its performance or reputation.
- The Group processes substantial volumes of personal and sensitive data and is required to comply with strict privacy and information security standards. Any failure to do so may adversely affect its relationships with patients and associates, expose the Group to legal claims and liability, or harm its reputation, leading to business disruptions and potential negative impact on the Group's financial standing.
- Failure to implement or comply with appropriate standards for diagnostic services may lead to errors and prevent the Group from meeting customer expectations regarding test quality, which could adversely affect its reputation and performance and expose it to legal claims.
- The Group's internal control systems, procedures, compliance functions, and risk management framework may not be sufficient to prevent or detect actual or potential legal or regulatory violations or to effectively manage risk.
- The Group relies on laboratory technologies provided by third-party vendors, and any limitations in access to these technologies or delays in equipment or reagent deliveries may have a material adverse effect on its test volumes and financial results.
- Failure to develop the Group's service offering or IT systems, or to maintain competitive pricing, could significantly undermine the competitiveness of its services or otherwise disrupt operations and customer relationships.
- Risk of a slowdown in the Group's organic growth.
- Significant changes in the rights or terms of access to property may have a material adverse effect on the Group's operations.
- The Group is exposed to risks associated with its strategy of acquiring small and medium-sized diagnostic service providers.
- The Group's organic growth strategy partly relies on the implementation of artificial intelligence and machine learning technologies, and any failure in their deployment or lack of adequate procedures and controls may give rise to legal and regulatory risks, harm the Group's reputation or otherwise have an adverse effect on the Group.
- The Group relies on the experience, knowledge, and skills of its laboratory staff, medical personnel authorised to collect or analyse biological material, and members of the Group's management team. A potential loss of these specialists, and the

Group's failure to replace them with individuals possessing comparable skills and expertise, may have an adverse effect on the Group.

- Disruptions in the Group's logistics network, including its courier operations, or deficiencies in biological specimen handling and transport may have an adverse effect on the Group's operations and financial performance.
- Disruption to the operation of a significant number of the Group's specimen collection points or laboratories, or of the Group's entire laboratory system, could result in increased operating expenses and adversely affect the Group's reputation.
- The Group relies on its strong and recognisable brand, and any loss of brand value, including due to negative customer opinions, may have a material adverse effect on its market position, operations, financial standing, and performance.
- If the Group is unable to maintain its competitive advantage in the medical laboratory testing market, this may adversely affect its operations, performance, financial standing, and growth prospects.
- The Group may be exposed to risks arising from the use of open-source and cloud-based solutions.
- The Group may face risks related to the collection of receivables, which may have a material effect on its operations, operating performance, and financial standing.
- Unfavourable outcomes in potential material proceedings, including court or administrative proceedings, may have adverse financial consequences for the Group and adversely affect the Group's reputation.
- The Group may be required to bear costs not covered by its insurance policies, which could have a material effect on its operations, financial performance, and financial standing.
- The Group has recognised a material amount of goodwill, which may be subject to impairment in the future, potentially affecting its financial performance.
- Credit facility agreements include covenants that restrict the ability of the Company and entities under its (direct or indirect) control to pay dividends and may limit their capacity for growth.
- Tax authorities' increased focus on related-party transactions may subject the Group's tax policies to closer scrutiny and expose the Group to tax audits and challenges related to such transactions.

Risks related to the Group's business environment

- The Group operates in a highly regulated environment. Compliance with applicable regulations may lead to increased operating expenses or limit the Group's operations, while non-compliance could result in various sanctions.
- An economic downturn in Poland or globally could have a material adverse effect on the Group's operations, financial standing, or operating performance.
- Growing competition from comparable market players in terms of both quality and pricing, coupled with continued consolidation in the diagnostic laboratory sector, may have a material adverse effect on the Group's revenue and profitability.
- Employee benefits expense, costs of raw materials and consumables, including laboratory materials and reagents, and costs of services may continue to grow significantly, which may have a material adverse effect on the Group's operations and financial performance.
- The Group generates and stores significant amounts of medical waste and is subject to strict regulations in this area. Non-compliance may result in administrative fines and additional sanctions.

More detailed information on the risks listed above is provided on page 47 of the Management Report on the operations of Diagnostyka S.A. and the Diagnostyka Group in 2025.

Diagnostyka+

Corporate governance

Group Structure

As at the reporting date, the Diagnostyka Group consisted of Diagnostyka S.A. as the Parent, and 30 subsidiaries, of which 6 are under the Parent's indirect control. The Group subsidiaries as at 30 June 2026 and 31 December 2025 are set out in the table below.

Subsidiary	Principal business	Principal place of business	Percentage ownership and voting interests held		Value of shares at cost	
			30 Jun 2026 (unaudited)	31 Dec 2025	30 Jun 2026 (unaudited)	31 Dec 2025
Diagnostyka Consilio Sp. z o.o.	medical laboratory testing services	Poland	100.00%	100.00%	31,613	31,613
Dr. N. Med. Teresa Fryda Laboratorium Medyczne Sp. z o.o.	medical laboratory testing services	Poland	100.00%	100.00%	485	485
Diagnostyka Oncogene Sp. z o.o.	medical laboratory testing services	Poland	66.67%	66.67%	2,782	2,782
Diagnostyka - Tarnów Medyczne Centrum Laboratoryjne Sp. z o.o.	medical laboratory testing services	Poland	50.61%	50.61%	4,394	4,394
Diagnostyka Genesis Sp. z o.o.	medical laboratory testing services	Poland	100.00%	100.00%	14,848	14,848
Longevity Plus Sp. z o.o.	medical laboratory testing services	Poland	100.00%	100.00%	2,506	2,506
Diagnostyka Consilio Poznań Sp. z o.o.*	medical laboratory testing services	Poland	70.26%	70.26%	3,298	3,298
Diag Invest Sp. z o.o.	property development	Poland	100.00%	100.00%	194,117	194,117
Histamed DC Sp. z o.o.*	medical laboratory testing services	Poland	74.00%	73.00%	3,033	3,032
Diagnostyka Digital Hub Sp. z o.o.	IT activities	Poland	100.00%	100.00%	3,378	3,378
Badania.pl Sp. z o.o.	medical laboratory testing services	Poland	90.00%	90.00%	4,337	4,337
Laboratoria Medyczne Novalab Sp. z o.o.	medical laboratory testing services	Poland	100.00%	100.00%	16,055	16,055

Niepubliczny Zakład Opieki Zdrowotnej Diagno-Med Sp. z o.o.*	medical laboratory testing services	Poland	74.00%	73.00%	5,901	5,901
Livmed Sp. z o.o.	diagnostic imaging services	Poland	89.95%	89.95%	47,520	47,520
Diagnostyka - Teleradiologia24 Sp. z o.o.	diagnostic imaging services	Poland	50.65%	50.65%	21,244	21,244
Zakład Rentgena i USG - Wyrobek Sp. z o.o.	diagnostic imaging services	Poland	53.75%	53.75%	18,375	17,975
Diagnostyka Plus Obrazowa Sp. z o.o.	diagnostic imaging services	Poland	100.00%	100.00%	100	100
Diagnostyka Wyrobek Sp. z o.o.*	diagnostic imaging services	Poland	78.66%	78.66%	44,927	44,927
Diagnostyka Obrazowa Bielsko-Biała Sp. z o.o.*	diagnostic imaging services	Poland	70.79%	70.79%	1,800	1,800
Eurodiagnostic Sp. z o.o.	lease of medical equipment	Poland	51.02%	51.02%	27,850	27,850
Diagnostyka Sp. z o.o.	diagnostic imaging services	Poland	100.00%	100.00%	11,762	11,762
Diagnostyka Obrazowa Bydgoszcz Sp. z o.o.	diagnostic imaging services	Poland	80.00%	80.00%	5,701	5,701
Niepubliczny Zakład Opieki Zdrowotnej Pracownia Genetyki Nowotworów Sp. z o.o.	medical laboratory testing services	Poland	100.00%	100.00%	9,775	9,775
Vita-Skan Sp. z o.o.	diagnostic imaging services	Poland	51.00%	51.00%	3,785	3,785
Centrum Medyczne Medix Sp. z o.o.	diagnostic imaging services	Poland	100.00%	100.00%	15,466	15,466
Diagnostyka Skamed Rezonans Sp. z o.o.	diagnostic imaging services	Poland	61.00%	0.00%	2,115	-
Instytut Mikroekologii Sp. z o.o.**	medical laboratory testing services	Poland	100.00%	50.50%	5,941	971
LAB-AD Sp. z o.o.	medical laboratory testing services	Poland	100.00%	0.00%	455	-
Wałowamed Sp. z o.o.*	diagnostic imaging services	Poland	55.06%	0.00%	1,265	-
Podkarpackie Centrum Genetyczne Oncogenlab Sp. z o.o.	medical laboratory testing services	Poland	100.00%	0.00%	3,168	-

* Subsidiaries in which the Group holds equity interests indirectly or over which it has indirect control.

** As at 31 December 2025, the company was classified in the category of jointly controlled entities and associates.

Detailed information on changes in the composition of the Group is provided in Note 1.3 to the consolidated financial statements for the six months ended 30 June 2026.

Shareholding structure

Shareholding structure of the Company as at the date of this report was as follows:

Shareholders	Nominal value (PLN)	Series of shares	% ownership interest	% voting interest
Grzegorz Głownia (holding shares directly and indi-rectly through ACER Capital Partners SCSp)	6,372,379	A	18.88%	25.65%
Jacek Prusek (holding shares directly and indirectly through ACACIA Capital Partners SCSp)	6,372,379	B	18.88%	25.65%
Jakub Swadźba	3,187,189	C, F	9.44%	12.83%
Other	17,824,953	D, E, F	52.80%	35.87%
Total	33,756,500		100.00%	100.00%

Holdings of Diagnostyka S.A. shares by other members of the Management Board and the Supervisory Board as at the date of issue of this report:

- 3,186,189 Series C registered shares carrying multiple-voting rights, and 1,000 Series F ordinary shares – Jakub Swadźba, President of the Management Board
- 235 Series F ordinary shares – Dariusz Zowczak, Vice President of the Management Board
- 5,000 Series F ordinary shares – Jaromir Pelczarski, Vice President of the Management Board
- 6,372,379 Series A registered shares carrying multiple-voting rights – Grzegorz Głownia (held directly and indirectly through ACER Capital Partners SCSp), Member of the Supervisor Board
- 6,372,379 Series B registered shares carrying multiple-voting rights – Jacek Prusek (held directly and indirectly through ACACIA Capital Partners SCSp), Member of the Supervisory Board
- 1,420,700 Series D ordinary shares – Marcin Fryda, Member of the Supervisory Board

There were no changes in holdings of Company shares by management andsupervisory personnel from the date of issue of the quarterly report for the three months ended 31 March 2026 to the date of issue of this report.

Dividend

Historical data on dividend payments

The table below presents information on dividends paid by the Company for the years ended 31 December 2025, 2024, 2023, 2022 and 2021.

Year ended 31 December	Net profit attributable to owners of the Parent (PLN thousand)	Dividend for the financial year (PLN thousand)	Dividend per share (PLN)	Dividend payout ratio (% of net profit attributable to owners of the Parent)
2021	557,791	492,251	14.58	88.3%
2022	167,415	112,072	3.32	66.9%
2023	123,430	105,658	3.13	85.6%
2024	223,326	111,734	3.31	50.0%
2025	251,603	148,529	4.40	59.0%

- **On 7 June 2022,**
  the Annual General Meeting resolved to pay a dividend to the Company's shareholders for the year ended 31 December 2021. The dividend amount was PLN 492,251,235.86, i.e. PLN 14.58 per share. Thus, the Company's entire net profit reported in the separate financial statements for the year ended 31 December 2021, totalling PLN 492,251,235.86, was allocated for distribution as dividend.

- **On 1 June 2023,**
  the Annual General Meeting resolved to pay a dividend to the Company's shareholders for the year ended 31 December 2022. The dividend amount was PLN 112,071,580.00, i.e. PLN 3.32 per share. The balance of the Company's profit for the year ended 31 December 2022, amounting to PLN 75,046,763.73, was allocated to the Company's statutory reserve funds.

- **On 6 September 2024,**
  the Annual General Meeting resolved to pay a dividend to the Company's shareholders for the year ended 31 December 2023. The dividend amount was PLN 105,657,845.00, i.e. PLN 3.13 per share. The balance of the Company's profit for the year ended 31 December 2023, amounting to PLN 11,868,155.00, was allocated to the Company's statutory reserve funds.

- **On 28 May 2025,**
  the Annual General Meeting resolved to pay a dividend to the Company's shareholders for the year ended 31 December 2024. The dividend amount was PLN 111,734,015.00, i.e. PLN 3.31 per share. The balance of the Company's profit for the year ended 31 December 2024, amounting to PLN 86,473,870.91, was allocated to the Company's statutory reserve funds.

- **On 25 May 2026,**
  the Annual General Meeting resolved to pay a dividend to the Company's shareholders for the year ended 31 December 2025. The dividend amount was PLN 148,528,600.00, i.e. PLN 4.40 per share. The balance of the Company's profit for the year ended 31 December 2025, amounting to PLN 84,585,157.67, was allocated to the Company's statutory reserve funds.

Dividend policy

In the coming years, the Management Board intends to recommend paying out dividends to shareholders for each financial year. When making its recommendation, the Management Board will consider:

- business-related constraints (in particular any restrictions on dividend payments set out in the Group's financing agreements), as well as legal limitations that may affect the amount available for distribution,
- the Group's financial standing (including extraordinary economic conditions or significant capital requirements),
- the Group's strategy and development plans. The recommendations will remain subject to market conditions and the factors outlined above.

The Management Board's intention is to recommend dividend distributions at a level of 50% of net profit attributable to owners of the Parent, with the option to increase the payout in years of exceptionally strong financial performance. The final decision on dividend distributions and amounts will be made by the General Meeting, taking into account the Group's financial condition, legal and credit obligations, and strategic growth plans.

The Management Board makes no assurance regarding the Company's future profits or any portion thereof that may be available for distribution as dividends. Any decision on the distribution and amount of a dividend rests entirely with the shareholders at the General Meeting, who are under no obligation to follow the Management Board's recommendation.

Management Board

Jakub Swadźba
President of the Management Board, Chief Executive Officer

In 1998, together with Grzegorz Głownia and Jacek Prusek, Jakub Swadźba co-founded Diagnostyka, now Poland's largest medical laboratory network. As President of the Management Board, he is responsible for key areas including growth strategy, leading the Management Board and overseeing the medical division.

Mr Swadźba holds the title of Habilitated Doctor of Medical Sciences and is a certified specialist in internal medicine, having completed his education at the Jagiellonian University Medical College and the Pomeranian Medical University. Alongside his executive role, he remains actively engaged in the medical community. He is the author and co-author of numerous scientific publications, a regular participant and speaker at industry conferences, and serves as Chair of Laboratory Medicine at the Andrzej Frycz Modrzewski Krakow University. He has received multiple prestigious awards, including the Wektory Award from Employers of Poland, the Polish Business Council Award, and EY Entrepreneur of the Year.

Dariusz Zowczak
Vice President of the Management Board, Chief Sales Officer (CSO)

Dariusz Zowczak joined Diagnostyka in 2004 and was appointed to its Management Board in 2007. His remit includes sales, acquisitions, development of the specimen collection point network, and oversight of the Company's regional divisions.

He holds degrees in medicine and economics, having graduated from the Medical University of Wrocław and the Wrocław University of Economics and Business. After completing his studies, he was involved in building the team at the Gynaecology and Obstetrics Department of the Provincial Hospital in Wrocław, contributed to the Medical Department of the Wrocław Province Branch of the National Health Fund (then operating as Kasa Chorych – Health Insurance Fund), and served as Medical Director of the T. Marciniak Specialist Hospital of the Wrocław Province.

Marta Rogalska-Kupiec
Vice President of the Management Board, Chief Operating Officer (COO)

Marta Rogalska-Kupiec has been working for the Diagnostyka Group since 2012 and has served as Vice President of the Management Board since August 2020. She is responsible for the Company's operations, oversees laboratory and specimen collection point coordination, and supervises the administrative and HR functions.

Her professional career began at the Institute of Molecular Biology at the Jagiellonian University in Kraków, where she worked as an associate lecturer from 1996 to 1998. She subsequently held the position of Head of Sales at Medicover (1999–2001) and then at Medar (2001–2003), and from 2003 to 2005 served as head of health services planning at the National Health Fund (Kraków Province Branch). Marta Rogalska-Kupiec holds a Master's degree in molecular biology from the Jagiellonian University in Kraków. She also completed postgraduate studies in human resources management and in integrated systems at the Kraków University of Economics.

Jaromir Pelczarski
Vice President of the Management Board, Chief Transformation Officer (CTO)

Jaromir Pelczarski joined Diagnostyka on 1 January 2025 as Vice President of the Management Board for IT Infrastructure. He is responsible for driving the Group's technological advancement, implementing modern digital solutions, and overseeing IT infrastructure management.

He has over 20 years of experience in international settings, having led technology transformation, system integration, and process digitalisation projects at some of the largest financial institutions.

At Alior Bank, he modernised the IT structure by introducing a Value Stream-based organisational model, significantly enhancing operational efficiency. At BNP Paribas, he oversaw one of the banking sector's largest technology mergers and developed data management systems and digital communication channels, improving their performance and increasing user engagement.

Changes in the composition of the Management Board after the reporting date

On 1 September 2026, the Management Board of Diagnostyka S.A. was joined by Jakub Tatak, who was appointed Vice President of the Management Board and Chief Financial Officer (CFO).

Jakub Tatak
Vice President of the Management Board, Chief Financial Officer (CFO)

As Vice President of the Management Board and Chief Financial Officer (CFO), Jakub Tatak is responsible for the Group's financial management, including controlling, accounting, treasury and tax. His remit also extends to investor relations. He is an experienced finance executive with a career spanning more than 25 years, including nearly 20 years in the healthcare sector. Before joining Diagnostyka, he served as Chief Financial Officer and Member of the Management Board of the LUX MED Group from 2018. His responsibilities included finance, acquisitions and the integration of acquired companies, as well as treasury, procurement, ESG and sustainability.

He also oversaw the implementation of AI and robotic automation, hospital operations, data management and subsidiaries. Earlier in his career, he held senior finance positions at First Data Polska S.A. and PolCard S.A. Jakub Tatak graduated from Lazarski University in Warsaw with a Master's degree in economics, and completed executive education programmes at IMD, INSEAD and Stanford University.

Supervisory Board

Artur Olender	Chair of the Supervisory Board
Jacek Prusek	Member of the Supervisory Board
Grzegorz Głownia	Member of the Supervisory Board
Marcin Fryda	Member of the Supervisory Board
Patrycja Swadźba	Member of the Supervisory Board
Paweł Leżański	Member of the Supervisory Board
Piotr Solorz	Member of the Supervisory Board
Aniela Hejnowska	Member of the Supervisory Board

Financial results

Financial results

Interim condensed consolidated statement of comprehensive income (PLN thousand)

	6M 2026	6M 2025	Q2 2026	Q2 2025
Revenue	**1,367,798**	**1,188,224**	**686,240**	**593,374**
Revenue from contracts with customers	1,353,932	1,179,855	683,016	588,303
Other operating income	13,866	8,369	3,224	5,071
Operating expenses	**-1,149,651**	**-973,194**	**-591,158**	**-490,574**
Depreciation and amortisation	-115,858	-97,204	-59,294	-50,121
Raw materials and consumables used	-288,549	-241,074	-151,092	-119,441
Services	-204,835	-166,809	-108,196	-85,815
Employee benefits expense	-506,406	-440,228	-254,082	-220,835
Taxes and charges	-17,856	-14,556	-8,732	-7,365
Other expenses by nature	-11,630	-8,769	-7,788	-5,079
Cost of goods for resale and materials sold	-2,227	-2,528	-1,095	-1,243
Impairment losses (including reversals of impairment losses) on trade receivables and other financial assets	-903	2	-177	394
Other operating expenses	-1,387	-2,028	-702	-1,069
Operating profit (loss)	**218,147**	**215,030**	**95,082**	**102,800**
Finance income	2,457	1,432	798	706
Finance costs	-33,454	-32,996	-16,248	-16,797
Share of profit or loss of associates and jointly controlled entities	125	205	-444	-182
Profit (loss) before tax	**187,275**	**183,671**	**79,188**	**86,527**
Income tax	**-40,897**	**-41,805**	**-18,735**	**-19,772**
NET PROFIT (LOSS)	**146,378**	**141,866**	**60,453**	**66,755**
Net profit attributable to:				
Owners of the Parent	139,947	136,668	57,392	63,809
Non-controlling interests	6,431	5,198	3,061	2,946
Earnings per share attributable to owners of the Parent:				
Basic earnings per share	4.15	4.05	1.70	1.89
Diluted earnings per share	4.15	4.05	1.70	1.89

	6M 2026	6M 2025	Q2 2026	Q2 2025
Other comprehensive income				
Total other comprehensive income	-	-	-	-
Total comprehensive income attributable to:	**146,378**	**141,866**	**60,453**	**66,755**
Owners of the Parent	139,947	136,668	57,392	63,809
Non-controlling interests	6,431	5,198	3,061	2,946

Interim condensed consolidated statement of financial position (PLN thousand)

Assets	As at 30 Jun 2026	As at 31 Dec 2025
Non-current assets	**1,776,105**	**1,700,850**
Property, plant and equipment	515,891	514,095
Right-of-use assets	490,452	459,489
Goodwill	496,604	478,091
Other intangible assets	187,076	174,574
Loans granted	36,643	29,199
Investments in associates and jointly controlled entities	39,034	36,321
Deferred tax assets	1,815	2,309
Non-current receivables	6,994	5,526
Non-current prepayments and accrued income	1,596	1,246
Current assets	**455,776**	**368,688**
Inventories	57,986	68,737
Trade receivables	345,842	258,281
Current tax assets	588	437
Loans granted	6,475	4,052
Public charges receivable	192	551
Other current receivables	9,074	7,812
Derivative instruments	-	1,765
Current prepayments and accrued income and other assets	18,055	8,629
Cash and cash equivalents	17,564	18,424
TOTAL ASSETS	**2,231,881**	**2,069,538**

Equity and liabilities	As at 30 Jun 2026	As at 31 Dec 2025
Equity	**527,321**	**547,192**
Share capital	33,757	33,757
Share premium	41,617	41,617
Capital reserve	305,845	207,762
Retained earnings	243,093	349,758
Other reserves	-114,414	-104,497
Equity attributable to owners of the Parent	509,898	528,397
Equity attributable to non-controlling interests	17,423	18,795
Non-current liabilities	**1,145,239**	**1,015,583**
Borrowings	735,417	627,714
Lease liabilities	344,810	305,243
Other financial liabilities	39,081	50,226
Employee benefit obligations	3,830	3,830
Deferred tax liabilities	17,576	24,024
Other liabilities and government grants	4,525	4,546
Current liabilities	**559,321**	**506,763**
Trade payables	160,356	134,960
Borrowings	7,311	6,085
Lease liabilities	133,971	141,602
Other financial liabilities	64,642	58,875
Current tax liabilities	21,678	7,431
Employee benefit obligations	93,070	83,158
Public charges payable	53,522	49,583
Other liabilities and government grants	24,771	25,069
TOTAL EQUITY AND LIABILITIES	**2,231,881**	**2,069,538**

Interim condensed consolidated statement of cash flows (PLN thousand)

	6M 2026	6M 2025
Profit (loss) before tax	**187,275**	**183,671**
Adjustments to profit before tax:	**147,691**	**129,416**
Share of profit or loss of associates and jointly controlled entities	-125	-205
Depreciation and amortisation	115,858	97,204
(Gain)/loss on investing activities	-4,463	-4,154
Net finance income/(costs)	31,653	32,035
Share-based payment plan	4,768	4,536
Adjustments due to changes in net working capital:	**-38,398**	**148**
(Increase)/decrease in trade and other receivables	-85,784	-19,028
(Increase)/decrease in inventories	10,985	-3,969
Increase/(decrease) in liabilities, excluding borrowings	46,029	32,062
Change in accruals and deferrals	-9,628	-8,917
Income tax paid	**-33,650**	**-18,132**
Net cash flows from operating activities	**262,918**	**295,103**
Cash flows from investing activities		
Proceeds from sale of property, plant and equipment and intangible assets	1,163	6,883
Payments to acquire property, plant and equipment and intangible assets	-67,007	-70,049
Proceeds from sale of investments in associates	-	35
Payments to acquire subsidiary and businesses, net of cash acquired	-36,342	-34,713
Payments to acquire shares of jointly controlled entities and associates	-4,733	-1,627
Dividends received	350	319
Interest received	33	1
Repayments of loans	2,036	-
Disbursements of loans	-10,644	-17,256
Net cash flows from investing activities	**-115,144**	**-116,407**

	6M 2026	6M 2025
Cash flows from financing activities		
Non-controlling interest in capital increase at subsidiaries	30	4,925
Acquisition of non-controlling interests	-	-2,220
Cash flows from derivative instruments (IRS)	1,900	3,854
Repayments of the principal portion of lease liabilities	-71,177	-64,043
Proceeds from borrowings	121,454	52,100
Repayments of borrowings	-14,209	-24,404
Interest on lease liabilities and borrowings	-32,149	-31,251
Dividends paid to owners of the Parent	-148,529	-111,734
Dividends paid to non-controlling interests	-5,954	-5,251
Net cash flows from financing activities	**-148,634**	**-178,024**
Net increase (decrease) in cash and cash equivalents	-860	672
Cash at the beginning of the period	**18,424**	**40,518**
Cash at the end of the period	**17,564**	**41,190**

Interim condensed consolidated statement of changes in equity for the six months ended 30 June 2026 (PLN thousand)

	Share capital	Share premium	Capital reserve	Retained earnings	Other reserves	Attributable to owners of the Parent	Attributable to non-controlling interests	Total
As at 1 January 2026	**33,757**	**41,617**	**207,762**	**349,759**	**-104,498**	**528,397**	**18,795**	**547,192**
Net profit for the year	-	-	-	139,947	-	139,947	6,431	146,378
Total comprehensive income	**-**	**-**	**-**	**139,947**	**-**	**139,947**	**6,431**	**146,378**
Allocation of profit to capital reserve	-	-	98,083	-98,083	-	-	-	-
Acquisition of non-controlling interests	-	-	-	-	80	80	-80	-
Put option on non-controlling interests	-	-	-	-	-14,763	-14,763	863	-13,900
Dividend payment	-	-	-	-148,529	-	-148,529	-8,769	-157,298
Acquisition of subsidiaries	-	-	-	-	-	-	182	182
Share-based payment plan	-	-	-	-	4,767	4,767	-	4,767
Non-controlling interest in capital increase at subsidiaries	-	-	-	-	-	-	-	-
Total changes in equity	-	-	98,083	-106,666	-9,916	-18,499	-1,372	-19,871
As at 30 June 2026	**33,757**	**41,617**	**305,845**	**243,093**	**-114,414**	**509,898**	**17,423**	**527,321**

Interim condensed consolidated statement of changes in equity for the six months ended 30 June 2025 (PLN thousand)

	Share capital	Share premium	Capital reserve	Retained earnings	Other reserves	Attributable to owners of the Parent	Attributable to non-controlling interests	Total
As at 1 January 2025	**33,757**	**41,617**	**107,841**	**309,810**	**-74,390**	**418,635**	**14,864**	**433,499**
Net profit for the year	-	-	-	136,668	-	136,668	5,198	141,866
Total comprehensive income	**-**	**-**	**-**	**136,668**	**-**	**136,668**	**5,198**	**141,866**
Allocation of profit to capital reserve	-	-	99,921	-99,921	-	-	-	-
Acquisition of non-controlling interests	-	-	-	-	-1,775	-1,775	-445	-2,220
Put option on non-controlling interests	-	-	-	-	-25,353	-25,353	-7,649	-33,001
Dividend payment	-	-	-	-111,734	-	-111,734	-6,211	-117,945
Acquisition of subsidiaries	-	-	-	-	-	-	3,236	3,236
Share-based payment plan	-	-	-	-	4,536	4,536	-	4,536
Non-controlling interest in capital increase at subsidiaries	-	-	-	-	-	-	4,925	4,925
Total changes in equity	-	-	99,921	-74,987	-22,592	2,342	-945	1,397
As at 30 June 2025	33,757	41,617	207,762	234,823	-96,982	420,977	13,919	434,896

Interim condensed separate statement of comprehensive income (PLN thousand)

	6M 2026	6M 2025	Q2 2026	Q2 2025
Revenue	**1,105,760**	**985,198**	**559,095**	**489,106**
Revenue from contracts with customers	1,101,196	980,661	557,150	487,366
Other operating income	4,564	4,537	1,945	1,740
Operating expenses	**-933,974**	**-805,693**	**-482,035**	**-405,449**
Depreciation and amortisation	-92,621	-81,237	-47,433	-41,338
Raw materials and consumables used	-242,809	-202,116	-127,548	-100,297
Services	-134,490	-115,039	-72,098	-59,160
Employee benefits expense	-436,228	-382,805	-219,349	-192,025
Taxes and charges	-15,117	-12,178	-7,325	-5,988
Other expenses by nature	-9,899	-7,765	-6,973	-4,498
Cost of goods for resale and materials sold	-2,195	-2,515	-1,089	-1,244
Impairment losses (including reversals of impairment losses) on trade receivables and other financial assets	-3	-553	276	-221
Other operating expenses	-612	-1,485	-496	-678
Operating profit (loss)	**171,786**	**179,505**	**77,060**	**83,657**
Finance income	38,840	27,376	37,382	26,273
Finance costs	-33,816	-33,115	-16,627	-17,488
Profit (loss) before tax	**176,810**	**173,766**	**97,815**	**92,442**
Income tax	-31,448	-34,969	-14,489	-16,319
NET PROFIT (LOSS)	**145,362**	**138,797**	**83,326**	**76,123**

	6M 2026	6M 2025	Q2 2026	Q2 2025
Other comprehensive income				
Change in fair value of equity financial instruments measured at fair value through other comprehensive income	2,944	107	-879	799
Items that will not be reclassified to profit or loss in subsequent reporting periods	**2,944**	**107**	**-879**	**799**
Total other comprehensive income	**2,944**	**107**	**-879**	**799**
Total comprehensive income	**148,306**	**138,904**	**82,447**	**76,922**

Interim condensed separate statement of financial position (PLN thousand)

Assets	As at 30 Jun 2026	As at 31 Dec 2025
Non-current assets	**1,694,299**	**1,627,973**
Property, plant and equipment	196,563	195,167
Right-of-use assets	483,647	459,890
Goodwill	301,289	296,527
Other intangible assets	127,300	111,511
Loans granted	54,381	54,975
Investments in associates and jointly controlled entities measured at cost	30,145	26,394
Investments in subsidiaries	484,580	472,500
Investments in associates measured at fair value	8,259	5,315
Non-current receivables	6,658	4,709
Non-current prepayments and accrued income and other assets	1,477	985
Current assets	**357,060**	**267,401**
Inventories	47,272	58,139
Trade receivables	233,417	167,130
Loans granted	25,147	24,361
Other current receivables	32,184	6,522
Derivative instruments	-	1,765
Current prepayments and accrued income and other assets	15,183	7,087
Cash and cash equivalents	3,857	2,397
TOTAL ASSETS	**2,051,359**	**1,895,374**

Equity and liabilities	As at 30 Jun 2026	As at 31 Dec 2025
Equity	**531,574**	**527,029**
Share capital	33,757	33,757
Share premium	41,617	41,617
Capital reserve	259,170	174,587
Retained earnings	183,337	271,087
Other reserves	13,693	5,981
Non-current liabilities	**1,050,428**	**919,145**
Borrowings	680,125	579,166
Lease liabilities	358,301	322,211
Employee benefit obligations	3,132	3,132
Deferred tax liabilities	6,416	12,105
Other liabilities and government grants	2,454	2,531
Current liabilities	**469,357**	**449,200**
Trade payables	143,033	121,350
Borrowings	31,579	29,276
Lease liabilities	125,640	135,341
Other financial liabilities	4,638	22,695
Current tax liabilities	18,519	3,599
Employee benefit obligations	82,438	74,279
Public charges payable	46,282	43,498
Other liabilities and government grants	17,228	19,162
TOTAL EQUITY AND LIABILITIES	**2,051,359**	**1,895,374**

Interim condensed separate statement of cash flows (PLN thousand)

	6M 2026	6M 2025
Profit (loss) before tax	176,810	173,766
Adjustments to profit before tax:	**91,840**	**88,656**
Depreciation and amortisation	92,621	81,237
(Gain)/loss on investing activities	-730	-1,731
Net finance income/(costs)	-4,819	4,615
Share-based payment plan	4,768	4,535
Adjustments due to changes in net working capital:	**-22,252**	**9,834**
(Increase)/decrease in trade and other receivables	-65,246	-11,800
(Increase)/decrease in inventories	10,868	-3,240
Increase/(decrease) in liabilities, excluding borrowings	40,714	33,893
Change in accruals and deferrals	-8,588	-9,019
Income tax paid	**-22,603**	**-10,295**
Net cash flows from operating activities	**223,795**	**261,961**
Cash flows from investing activities		
Proceeds from sale of property, plant and equipment and intangible assets	866	1,793
Payments to acquire property, plant and equipment and intangible assets	-53,353	-56,280
Proceeds from sale of investments in associates	-	35
Payments to acquire businesses, net of cash acquired	-6,540	-9,630
Payments to acquire shares in subsidiaries, associates and jointly controlled entities	-35,408	-38,286
Dividends received	10,692	15,003
Interest received	957	925
Repayments of loans	11,857	5,344
Disbursements of loans	-10,644	-24,703
Net cash flows from investing activities	**-81,573**	**-105,799**
Cash flows from financing activities		
Repayments of the principal portion of lease liabilities	-65,375	-59,463
Proceeds from borrowings	112,510	61,238
Repayments of borrowings	-9,984	-20,278
Cash flows from derivative instruments (IRS)	1,900	3,854
Interest on lease liabilities and borrowings	-31,284	-30,208
Dividends paid	-148,529	-111,734
Net cash flows from financing activities	**-140,762**	**-156,591**
Net increase (decrease) in cash and cash equivalents	1,460	-429
Cash at the beginning of the period	**2,397**	**2,867**
Cash at the end of the period	**3,857**	**2,438**

Interim condensed separate statement of changes in equity for the six months ended 30 June 2026 (PLN thousand)

	Share capital	Share premium	Capital reserve	Retained earnings	Other reserves	Total
As at 1 January 2026	**33,757**	**41,617**	**174,587**	**271,087**	**5,981**	**527,029**
Net profit for the year	-	-	-	145,362	-	**145,362**
Measurement of shares in GenXone	-	-	-	-	2,944	**2,944**
Total comprehensive income	-	-	-	145,362	2,944	**148,306**
Allocation of profit to capital reserve	-	-	84,583	-84,583	-	-
Dividend payment	-	-	-	-148,529	-	**-148,529**
Share-based payment plan	-	-	-	-	4,768	**4,768**
Total changes in equity	-	-	84,583	-87,750	7,712	**4,545**
As at 30 June 2026	**33,757**	**41,617**	**259,170**	**183,337**	**13,693**	**531,574**

Interim condensed separate statement of changes in equity for the six months ended 30 June 2025 (PLN thousand)

	Share capital	Share premium	Capital reserve	Retained earnings	Other reserves	Total
As at 1 January 2025	**33,757**	**41,617**	**88,113**	**236,183**	**1,673**	**401,343**
Net profit for the year	-	-	-	138,797	-	**138,797**
Measurement of shares in GenXone	-	-	-	-	107	**107**
Total comprehensive income	-	-	-	138,797	107	**138,904**
Allocation of profit to capital reserve	-	-	86,474	-86,474	-	-
Dividend payment	-	-	-	-111,734	-	**-111,734**
Share-based payment plan	-	-	-	-	4,535	**4,535**
Total changes in equity	-	-	86,474	-59,411	4,642	**31,705**
As at 30 June 2025	**33,757**	**41,617**	**174,587**	**176,772**	**6,315**	**433,048**

Other information

Other information

Sureties and guarantees

+ As at 30 June 2026, the Group continued to use its bank-guarantee facility with BNP Paribas; utilisation rose by PLN 280 thousand versus 31 December 2025, to PLN 3,565 thousand.
+ The amount of sureties issued by the Parent on behalf of subsidiaries in connection with their lease contracts decreased by PLN 1,333 thousand compared with year-end 2025, to PLN 1,148 thousand as at 30 June 2026.

Debt

Detailed information on the Company's debt is provided in Note 19 to the consolidated financial statements.

	30 Jun 2026	31 Dec 2025
At amortised cost	**742,728**	**633,799**
Overdraft facilities	315,088	295,917
Credit facilities	400,809	318,347
Non-bank borrowings	26,832	19,535
Lease liabilities	**478,781**	**446,845**
Lease liabilities	478,781	446,845
Borrowings and lease liabilities	**1,221,509**	**1,080,644**
Current liabilities under borrowings and leases	141,282	147,687
Non-current liabilities under borrowings and leases	1,080,227	932,957

Borrowings

For details on the Company's borrowings, see Note 19 'Borrowings' to the consolidated financial statements.

Events after the reporting date

+ On 1 July 2026, the merger of Diagnostyka S.A. with its subsidiary Laboratoria Medyczne Novalab Sp. z o.o. was registered.
+ On 3 August 2026, the merger of Histamed DC Sp. z o.o. with its subsidiary Niepubliczny Zakład Opieki Zdrowotnej Diagno-Med Sp. z o.o. was registered.

For details of events subsequent to the reporting date, see Note 25 to the consolidated financial statements.

Financial forecasts

The Management Board has not published any financial forecasts.

Feasibility of investment plans

The Group has the capacity to carry out its investment plans, including equity investments, using both internal funds and debt financing.

Court proceedings

A description of litigation matters is provided in Note 20.2 to the consolidated financial statements for the six months ended 30 June 2026.

Selected one-off, non-recurring or non-standard items affecting the Group's financial position and results

In the period ended 30 June 2026, the Group did not identify any one-off, non-recurring or non-standard items compared with the Group's results reported in the ordinary course of business.

Related-party transactions entered into by the Company or its subsidiaries on terms other than arm's length

The Parent and its subsidiaries do not conclude any related-party transactions on non-arm's length terms.

Management Board of Diagnostyka S.A.

Name	Title	Signature
Jakub Swadźba	President of the Management Board	
Jakub Tatak	Vice President of the Management Board	
Dariusz Zowczak	Vice President of the Management Board	
Marta Rogalska-Kupiec	Vice President of the Management Board	
Jaromir Pelczarski	Vice President of the Management Board	